companydata.dkcompanydata.dk

Renovaro Biosciences Denmark ApS: Financial statements 2020

CVR: 26027322

Source: annual report 2020, Danish Business Authority

01/07/2019 – 30/06/2020

Renovaro Biosciences Denmark ApS (CVR 26027322) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -1,113,727 and a net result of DKK -1,708,076 compared with DKK -6,845,472 the year before. Equity in the 2020 report amounted to DKK -64,346,720. The company had 1 employee in the financial year.

Gross Profit
DKK -1,113,727
Profit/Loss
DKK -1,708,076
Equity
DKK -64,346,720
Total Assets
DKK 5,680,351
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2020--1.1M-1.7M-64.3M1
2019--1.9M-6.8M-62.6M1
2018--4.5M-7M-55.8M-
2016--5M-10.7M-52M2
2015--17.4M-20.4M-41.3M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Renovaro Biosciences Denmark ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

About Renovaro Biosciences Denmark ApS

Renovaro Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2001. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Enochian BioSciences Denmark ApS and DanDrit Biotech ApS. The management consists of David Hershel Weinstein. The company is owned by Lunai Bioworks Inc.. The company has 1 employee (2017). In 2026, the company reported a gross profit of DKK -4,478 and a net result of DKK -1,178,038 compared with DKK -4,629,959 the year before. Equity in the 2026 report amounted to DKK -91,933,986.

Source: annual report 2026, Danish Business Authority